• Haoxin reported FY2025 net income of USD 3.97 million, up 25%.
• Revenue rose 29.2% to USD 33.04 million, driven by new customers.
• Operating income climbed 40.6% to USD 7.79 million.
• Liquidity strengthened with cash and restricted cash of USD 1.41 million; working capital expanded to USD 26.5 million on higher business-related receivables.
• Haoxin said it plans to build cold temperature warehouses and add pharmaceutical logistics capabilities; it expects revenue and operations to continue to grow.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Haoxin Holdings Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-050203), on April 30, 2026, and is solely responsible for the information contained therein.